Ina M. Pretzell
Essen, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond.
Journal: Targeted oncology
Published: May 12, 2026
LLM-Generated Lay-Language Protocols for Molecular Tumor Board Patients: Evaluation of Quality and Clinical Usability.
Journal: Journal of medical Internet research
Published: April 22, 2026
Escape From Synthetic T Cell Activator Tebentafusp by Genomic HLA Loss: A Case Report.
Journal: HLA
Published: February 01, 2026
Primary Angiosarcomas of the Thyroid: New Insights Into the Genetic Background and Potentially Targetable Therapeutic Markers of an Ultrarare Disease.
Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Published: December 08, 2025
Moving Tumor-Agnostic Therapy to the Big Stage: Translational and Molecular Oncology Highlights from the ESMO Congress 2025.
Journal: Oncology research and treatment
Published: December 01, 2025
Exceptional therapeutic benefit of imatinib in cKIT-mutated mucosal melanoma followed by a KIT mutation loss.
Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Published: March 10, 2025
90Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous Tumors.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: January 21, 2025
Precision oncology - Guideline of the Austrian, German and Swiss Societies for hematology and medical oncology.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 20, 2025
Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123).
Journal: Journal of cancer research and clinical oncology
Published: July 24, 2024
PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitors.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 26, 2024
What Do German Molecular Tumor Boards Recommend in Patients with PIK3CA-Mutated Tumors? Launch and First Results from the German Transsectoral Molecular Tumor Board Exchange Platform Deutschland.
Journal: Oncology research and treatment
Published: February 03, 2024
Last Updated: 09/26/2026